Please login to the form below

Not currently logged in
Email:
Password:

GW Pharmaceuticals

This page shows the latest GW Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Cancer pain: opioids set to dominate

Cancer pain: opioids set to dominate

Phase III: opioid agonists. GW Pharmaceuticals has developed a buccal spray known as nabiximols or Sativex, which comprises delta-9-tetrahydrocannabinol (27mg/mL) and cannabidiol (25mg/mL), as an analgesic agent ... WEX Pharmaceuticals is conducting a

Latest news

  • Almirall launches Sativex in Italy Almirall launches Sativex in Italy

    The drug, developed by GW Pharmaceuticals, was approved by Italian authorities in May and comes to the market with a reimbursed priced that GW said was “ consistent with the reimbursed … price ... Sativex has been given a rolling launch in Europe,

  • GW Pharma says German Sativex pricing GW Pharma says German Sativex pricing "unacceptable"

    GW Pharma says German Sativex pricing "unacceptable". May pull MS drug from market. ... GW Pharmaceuticals and partner Almirall have said they may pull Sativex from the market in Germany after failing to agree a price for the drug with the national

  • Almirall files cannabis-based MS drug Sativex in additional EU markets

    by GW Pharmaceuticals. ... It is manufactured by GW Pharma under Home Office licence at an undisclosed location in the UK, and represents the first new therapeutic class to treat spasticity in over 10 years.

  • Novartis gains licence for GW's Sativex

    Novartis gains licence for GW's Sativex. GW Pharmaceuticals has entered into an exclusive licence agreement for Novartis to commercialise Sativex in several key territories. ... GW Pharmaceuticals has entered into an exclusive licence agreement for

  • Thin on the ground

    Aztreonam. APP Pharmaceuticals. Gram-negative infections. US. Candesartan cilexetil/amlodipine. Unisia (Takeda). Hypertension. ... Japan. Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD. Sativex (GW Pharmaceuticals). Spasticity due to multiple

More from news
Approximately 0 fully matching, plus 42 partially matching documents found.

Latest appointments

  • GW Pharmaceuticals strengthens research and development team GW Pharmaceuticals strengthens research and development team

    GW Pharmaceuticals strengthens research and development team. Appoints Dr Volker Knappertz and Professor Ben Whalley. ... GW Pharmaceuticals has appointed Dr Volker Knappertz (pictured right) as its chief medical officer (CMO), a role that will see him

  • GW Pharmaceuticals promotes Adam George to MD GW Pharmaceuticals promotes Adam George to MD

    GW Pharmaceuticals promotes Adam George to MD. And Scott Giacobello joins as chief financial officer. ... UK biopharma company GW Pharmaceuticals has promoted chief financial officer Adam George to UK managing director.

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    GW hires Pfizer’ s Kenneth Sommerville. Appointed VP clinical research at company specialising in cannabinoids. ... Dr Kenneth Sommerville has left his role at pharma giant Pfizer to join GW Pharma.

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics